126 related articles for article (PubMed ID: 1606291)
21. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
Weitz JI; Leslie B; Ginsberg J
J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
[TBL] [Abstract][Full Text] [Related]
22. [Disorders of hemostasis after polytrauma. On the extent of intrinsic fibrinolytic activity in the preclinical phase].
Lampl L; Bock KH; Hartel W; Helm M; Tisch M; Seifried E
Chirurg; 1992 Apr; 63(4):305-9. PubMed ID: 1597093
[TBL] [Abstract][Full Text] [Related]
23. Thyroid dysfunction and fibrin network structure: a mechanism for increased thrombotic risk in hyperthyroid individuals.
Hooper JM; Stuijver DJ; Orme SM; van Zaane B; Hess K; Gerdes VE; Phoenix F; Rice P; Smith KA; Alzahrani SH; Standeven KF; Ajjan RA
J Clin Endocrinol Metab; 2012 May; 97(5):1463-73. PubMed ID: 22378816
[TBL] [Abstract][Full Text] [Related]
24. Markers of thrombin and plasmin generation in patients with inherited thrombophilia.
Lee LH; Jennings I; Luddington R; Baglin T
J Clin Pathol; 1994 Jul; 47(7):631-4. PubMed ID: 8089219
[TBL] [Abstract][Full Text] [Related]
25. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis.
Declerck PJ; Mombaerts P; Holvoet P; De Mol M; Collen D
Thromb Haemost; 1987 Dec; 58(4):1024-9. PubMed ID: 3127914
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic possibilities of specific fibrin(ogen) degradation products in relation to venous thromboembolism.
Haas FJ; Schutgens RE; Biesma DH; Laterveer RH; Kluft C
Blood Coagul Fibrinolysis; 2013 Apr; 24(3):297-304. PubMed ID: 23187785
[TBL] [Abstract][Full Text] [Related]
27. A plasma clot lysis assay based on the release of fibrin degradation products: application to the diagnosis of hypofibrinolytic states.
Gaussem P; Gandrille S; Molho-Sabatier P; Capron L; Fiessinger JN; Aiach M
Thromb Haemost; 1990 Feb; 63(1):76-81. PubMed ID: 2111050
[TBL] [Abstract][Full Text] [Related]
28. Soluble fibrin monomer degradation products as a potentially useful marker for hypercoagulable states with accelerated fibrinolysis.
Ieko M; Nakabayashi T; Tarumi T; Naito S; Yoshida M; Kanazawa K; Mizukami K; Koike T
Clin Chim Acta; 2007; 386(1-2):38-45. PubMed ID: 17803984
[TBL] [Abstract][Full Text] [Related]
29. Thrombin activation and increased fibrinolysis in patients with chronic liver disease.
Páramo JA; Rifón J; Fernández J; Cuesta B; Rocha E
Blood Coagul Fibrinolysis; 1991 Apr; 2(2):227-30. PubMed ID: 1909901
[TBL] [Abstract][Full Text] [Related]
30. Markers of coagulation and fibrinolysis as measures of disease activity in inflammatory bowel disease.
Kjeldsen J; Lassen JF; Brandslund I; Schaffalitzky de Muckadell OB
Scand J Gastroenterol; 1998 Jun; 33(6):637-43. PubMed ID: 9669637
[TBL] [Abstract][Full Text] [Related]
31. Plasma coagulation profiles in patients with severe primary pulmonary hypertension.
Hoeper MM; Sosada M; Fabel H
Eur Respir J; 1998 Dec; 12(6):1446-9. PubMed ID: 9877507
[TBL] [Abstract][Full Text] [Related]
32. Markers of coagulation and fibrinolysis in portal blood from patients with and without gastric malignancy.
Rahr HB; Sørensen JV; Larsen JF; Jensen FS; Bredahl C
Scand J Gastroenterol; 1994 Jun; 29(6):516-21. PubMed ID: 8079109
[TBL] [Abstract][Full Text] [Related]
33. Dysfunctional coagulation and fibrinolysis systems due to adenomyosis is a possible cause of thrombosis and menorrhagia.
Yamanaka A; Kimura F; Yoshida T; Kita N; Takahashi K; Kushima R; Murakmai T
Eur J Obstet Gynecol Reprod Biol; 2016 Sep; 204():99-103. PubMed ID: 27543913
[TBL] [Abstract][Full Text] [Related]
34. Use of fibrinogen and fibrin D-dimer in prediction of arterial thrombotic events.
Lowe GD; Rumley A
Thromb Haemost; 1999 Aug; 82(2):667-72. PubMed ID: 10605766
[No Abstract] [Full Text] [Related]
35. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension.
Eisenberg PR; Lucore C; Kaufman L; Sobel BE; Jaffe AS; Rich S
Circulation; 1990 Sep; 82(3):841-7. PubMed ID: 2394005
[TBL] [Abstract][Full Text] [Related]
36. Plasma fibrinogen, fibrinolytic activity and serum fibrinogen/fibrin degradation products in ischaemic heart disease.
Dube B; Somani PN; Tripathi GK; Dube RK; Bhattacharya SK
J Assoc Physicians India; 1985 Dec; 33(12):784-5, 787. PubMed ID: 3837002
[No Abstract] [Full Text] [Related]
37. Fibrinogenolysis and fibrinolysis with strenuous exercise.
Ferguson EW; Barr CF; Bernier LL
J Appl Physiol Respir Environ Exerc Physiol; 1979 Dec; 47(6):1157-61. PubMed ID: 536284
[TBL] [Abstract][Full Text] [Related]
38. [The role of DL and DH degradation products in the reactions of the plasmin hydrolysis of fibrinogen and fibrin].
Rozenfel'd MA; Leonova VB; Khavkina LS
Izv Akad Nauk SSSR Biol; 1991; (3):334-42. PubMed ID: 1835465
[TBL] [Abstract][Full Text] [Related]
39. The role of coagulation, fibrinogenolysis and fibrinolysis in the development of fluid and clotted cadaver plasma.
Klaubert W; Schönbauer R; Gilg T; Gollwitzer R; Hafter R; Graeff H; Spann W; Wilmanns W
Thromb Res; 1988 Apr; 50(1):53-63. PubMed ID: 3400085
[TBL] [Abstract][Full Text] [Related]
40. The use of high dose aprotinin in liver transplantation: the influence on fibrinolysis and blood loss.
Grosse H; Lobbes W; Frambach M; von Broen O; Ringe B; Barthels M
Thromb Res; 1991 Aug; 63(3):287-97. PubMed ID: 1720262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
